ABSTRACT

In the present research work, Rifabutin, drug used for tuberculosis infection, was encapsulated in lipidic nanoparticles with a view to develop a sustained release oral formulation. The nanocarrier loaded rifabutin, prepared by the solvent diffusion evaporation method and evaluated for its physical (nanoparticles size distribution) and chemical (drug content) stability. To optimize the identified independent variables, Box-Behnken Design (BBD) was utilized effectively. The result showed that a size of optimized formulation was found to be 315 ± 10.96 nm and PDI of 0.310 ± 0.05; the encapsulation efficiency was found to be (66.3 ± 3.85). On encapsulation, the nanocarrier showed amorphous pattern of drug studied using X-ray Diffractometric analysis. The release pattern of rifabutin loaded nanocarrier revealed that it represents the sustained release kinetics in comparison to plain drug. Thus, nanotechnology-based formulation may reduce frequency, provide medications more efficaciously, ultimately reducing patient avoidance.

摘要

在目前的研究工作中，用于结核感染的药物利福布丁被包裹在脂质纳米颗粒中，以开发一种缓释口服制剂。载有利福布丁的纳米载体，通过溶剂扩散蒸发法制备，并评估其物理（纳米颗粒尺寸分布）和化学（药物含量）稳定性。为了优化确定的自变量，Box-Behnken Design (BBD) 得到了有效利用。结果表明，优化后的配方尺寸为315±10.96 nm，PDI为0.310±0.05；发现封装效率为（66.3±3.85）。在封装时，纳米载体显示出使用 X 射线衍射分析研究的药物的无定形图案。载有利福布汀的纳米载体的释放模式表明，与普通药物相比，它代表了缓释动力学。因此，基于纳米技术的配方可以减少频率，更有效地提供药物，最终减少患者的回避。